Drug Profile
IMA 901
Alternative Names: IMA-901; Renal cancer vaccine - Immatics N.V.Latest Information Update: 07 Jul 2020
Price :
$50
*
At a glance
- Originator immatics biotechnologies GmbH
- Class Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Renal cell carcinoma
Most Recent Events
- 01 Jul 2020 Immatics N.V and Immatics Biotechnologies GmbH combined to form Immatics N.V.
- 03 May 2016 Discontinued - Phase-II for Renal cell carcinoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain, Switzerland, Slovakia, Bulgaria, Austria (Intradermal) (Immatics pipeline, May 2016)
- 03 May 2016 Discontinued - Phase-III for Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease) in Germany, USA, France, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, United Kingdom (Intradermal) (Immatics pipeline, May 2016)